HUTCHMED (NASDAQ:HCM) Shares Gap Down – What’s Next?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $14.56, but opened at $13.78. HUTCHMED shares last traded at $14.0690, with a volume of 1,408 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts have commented on HCM shares. Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a research note on Thursday, January 22nd. Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Bank of America lowered their price target on HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $16.88.

HUTCHMED Trading Up 0.9%

The stock has a fifty day moving average price of $14.61 and a 200 day moving average price of $14.62. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96.

HUTCHMED (NASDAQ:HCM) last posted its earnings results on Friday, March 6th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $2.50 by ($2.49). The company had revenue of $135.42 million during the quarter, compared to analysts’ expectations of $290.50 million. Research analysts expect that HUTCHMED will post 0.41 earnings per share for the current year.

Institutional Trading of HUTCHMED

Institutional investors and hedge funds have recently modified their holdings of the company. Janney Montgomery Scott LLC acquired a new position in HUTCHMED in the 1st quarter valued at $365,000. State Street Corp raised its holdings in HUTCHMED by 1.2% in the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after acquiring an additional 3,801 shares during the period. Renaissance Technologies LLC lifted its position in HUTCHMED by 3.0% during the 4th quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $1,798,000 after acquiring an additional 3,900 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in HUTCHMED by 157.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock worth $746,000 after acquiring an additional 34,248 shares during the last quarter. Finally, M&G PLC boosted its holdings in HUTCHMED by 26.7% during the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after acquiring an additional 54,601 shares during the period. 8.82% of the stock is currently owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.